COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
ConclusionsComorbidities, obesity, and Black/African ancestry, but not age, were associated with a higher risk of SARS-CoV-2 infection in PwMS. Interferons and glatiramer acetate were associated with a reduced COVID-19 risk, whereas anti-CD20 therapies were associated with an increased risk, within the treated MS cohort. COVID-19 safety reports for patients receiving Biogen MS therapies were consistent with the Explorys database and MS literature, illustrating the replicability and power of this approach.
Source: CNS Drugs - Category: Neurology Source Type: research
More News: African Health | Avonex | Copaxone | Coronavirus | COVID-19 | Databases & Libraries | Eating Disorders & Weight Management | Electronic Health Records (EHR) | Lupus | Multiple Sclerosis | Neurology | Obesity | Rebif | Respiratory Medicine | SARS | Study | Tysabri